At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Centanafadinedrug
Likely dose
Centanafadine 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Oct 4, 2021·Updated Jun 13, 2025
In Brief
A Phase 2 clinical trial evaluating Centanafadine for Smoking Cessation. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedOct 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedOct 4, 2021
Enrollment StartSep 15, 2021
Primary CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.7 years ago
Interventions
Centanafadinedrug
400 mg total daily dose Centanafadine Sustained Release, oral tablets